Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine

被引：2
|
作者：
Zhang, Yangyang [1 ]
Liu, Minghua [1 ]
Wang, Jun [1 ]
Huang, Jianlin [1 ]
Guo, Mingyue [1 ]
Zuo, Ling [1 ]
Xu, Biantiao [1 ]
Cao, Shousong [1 ]
Lin, Xiukun [1 ]
机构：
[1] Southwest Med Univ, Sch Pharm, Dept Pharmacol, 319 Zhongshan Rd, Luzhou 646000, Sichuan, Peoples R China
来源：
CURRENT DRUG TARGETS | 2019年 / 20卷 / 15期
基金：
美国国家科学基金会;
关键词：
Traditional chinese medicine; protein kinase inhibitors; anticancer activity; PI3K/AKT/mTOR; MAPK; ERK; HUMAN HEPATOCELLULAR-CARCINOMA; APOPTOTIC CELL-DEATH; N-TERMINAL KINASE; HUMAN OSTEOSARCOMA; IN-VITRO; BETA-ELEMENE; CANCER-CELLS; SIGNALING PATHWAY; DOWN-REGULATION; CYCLE ARREST;
D O I：
10.2174/1389450120666190802125959
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Protein kinases play critical roles in the control of cell growth, proliferation, migration, and angiogenesis, through their catalytic activity. Over the past years, numerous protein kinase inhibitors have been identified and are being successfully used clinically. Traditional Chinese medicine (TCM) represents a large class of bioactive substances, and some of them display anticancer activity via inhibiting protein kinases signal pathway. Some of the TCM have been used to treat tumors clinically in China for many years. The p38mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase, serine/threonine-specific protein kinases (PI3K/AKT/mTOR), and extracellular signal-regulated kisses (ERK) pathways are considered important signals in cancer cell development. In the present article, the recent progress of TCM that exhibited significant inhibitory activity towards a range of protein kinases is discussed. The clinical efficacy of TCM with inhibitory effects on protein kinases in treating a tumor is also presented. The article also discussed the prospects and problems in the development of anticancer agents with TCM.
引用
收藏
页码：1505 / 1516
页数：12
相关论文